Table 2.
Results of meta-analysis.
| No. of studies | HR | 95% CI | p value | I2 (%) | P heterogeneity | |
|---|---|---|---|---|---|---|
| Overall survival | 11 | 0.78 | 0.59–1.04 | 0.089 | 0.0 | 0.456 |
| Stage | ||||||
| T1 | 8 | 0.80 | 0.59–1.08 | 0.140 | 21.7 | 0.257 |
| T1a | 3 | 0.69 | 0.31–1.53 | 0.362 | 0.0 | 0.683 |
| Tumor type | ||||||
| Adenocarcinoma | 3 | 0.56 | 0.15–2.07 | 0.384 | 0.0 | 0.441 |
| Squamous cell carcinoma | 6 | 0.65 | 0.47–0.91 | 0.013 | 0.0 | 0.696 |
| Disease-specific survival | 6 | 0.56 | 0.39–0.82 | 0.003 | 19.5 | 0.287 |
| Tumor-type | ||||||
| Squamous cell carcinoma | 3 | 0.60 | 0.35–1.02 | 0.057 | 0.0 | 0.872 |
| Adenocarcinoma | 1 | 0.29 | 0.14–0.61 | 0.001 | - | - |
HR, hazard ratio; CI, confidence interval.
Bold values indicate significant statistical difference.